Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS-00491
- Development stage
- Preclinical
- Lead developer
- Ascentage Pharma
- Modality
- Small Molecules
01
Overview
AS-00491 is an experimental, small-molecule inhibitor of the anti-apoptotic protein myeloid cell leukemia 1 (MCL-1), being developed by Ascentage Pharma as an apoptosis-stimulating anticancer agent. By binding with high affinity to MCL-1 and disrupting its interaction with pro-apoptotic BCL-2 family proteins, AS-00491 is designed to restore mitochondrial apoptosis in MCL-1–dependent tumor cells, with a development focus on hematologic malignancies and solid tumors that rely on MCL-1 for survival.[6][7]
- Other names
- AS-00491AS00491AS 00491
02
Targets
MCL1 (Myeloid cell leukemia sequence 1)
Beyond the preview
Go deeper on AS-00491.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS-00491.